XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015
March 05 2015 - 4:05PM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of therapeutic antibodies, announced today the results
from its Phase 1 first-in-human study of XOMA 358, an allosteric
modulating monoclonal antibody that binds to insulin receptors and
attenuates insulin action, will be presented at the Endocrine
Society's 97th Annual Meeting, taking place from March 5-8, 2015,
in San Diego, California.
The details of the presentation are included below:
Title: XOMA 358, a Novel Treatment for
Hyperinsulinemic Hypoglycemia: Safety and Clinical Pharmacology
from the First in Human Trial
Session: LBS 097-116-Late-breaking Diabetes
& Glucose Metabolism III
Date: Saturday, March 7, 2015
Time: 1:00 – 3:00pm PT
Presenter: Rajneesh Nath, PhD, Vice President,
Clinical Science at XOMA
Location: LBS-104 (Hall D-F, Diabetes)
About XOMA 358
Insulin is the major hormone for lowering blood glucose levels.
Abnormal increases in insulin secretion can lead to profound
hypoglycemia (low blood sugar), a state that can result in
significant morbidities including cerebral damage and epilepsy. In
some instances, profound hypoglycemia can be fatal. XOMA 358 is a
fully human allosteric modulating monoclonal antibody that binds to
insulin receptors and attenuates insulin action. XOMA 358 is being
investigated as a novel treatment for non-drug-induced, endogenous
hyperinsulinemic hypoglycemia (low blood glucose caused by
excessive insulin production) and other related disorders. A
therapy that safely and effectively mitigates insulin-induced
hypoglycemia has the potential to address a significant unmet
therapeutic need for certain rare medical conditions associated
with hyperinsulinism.
About XOMA Corporation
XOMA's innovative product candidates are the result of the
Company's expertise in developing ground-breaking monoclonal
antibodies, including allosteric modulating antibodies, which have
created new opportunities to potentially treat a wide range of
human diseases. XOMA is developing its lead product gevokizumab
(IL-1 beta modulating antibody) with SERVIER through a global Phase
3 program for Behçet's disease uveitis, non-infectious uveitis and
pyoderma gangrenosum. XOMA's scientific research also produced
the XMet program, which consists of three classes Selective Insulin
Receptor Modulators (SIRMs) antibodies. XOMA 358, the lead
antibody in the XMetD program, is a first-in-class allosteric
modulating monoclonal antibody that reduces both the binding of
insulin to its receptor and downstream insulin signaling, which
could have a major effect on the treatment of abnormal metabolic
states.
More detailed information can be found at www.xoma.com.
CONTACT: Company and Investor Contacts:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
XOMA Royalty (NASDAQ:XOMA)
Historical Stock Chart
From Aug 2024 to Sep 2024
XOMA Royalty (NASDAQ:XOMA)
Historical Stock Chart
From Sep 2023 to Sep 2024